

A LOSS OF TIME?

Abbas Zahedi y Alberto Vallejo

14.10.21 Juf

Abbas Zahedi



Rhizome Analysis: Turmeric

2016



Rhizome Analysis: Galangal

2016




Rhizome Analysis: Ginger

2016




Centrifugal Pump Assemblage

2016




Malt Mixture Methodology

2016



Plato Lemon

2016



The Lemons the sicilians are
sending us are not the
same as they sent ^{waiting}
before / There's a galangal /
outside your house / It's knocking
on your front door.... open up!

Malady, Malaise, Maladaptation

04/07/00

(63)

Time to get 'Movin'

Parkinson's & vesicular transporters

Introduction:

Parkinson's disease (PD) is a debilitating progressive neurodegenerative disorder which affects at least 1% of the global population. Furthermore it has been documented that every general practitioner in the United Kingdom treats multiple patients with the disease, and there is yet to exist a general consensus on the most its most effective therapy¹. Symptoms of PD are typified by the slowness or loss of movement (akinesia), muscle stiffness, rigidity, and resting tremors affecting the extremities. The underlying cause of the disease is loss of neural connectivity between the substantia nigra (SN) and caudate-striatum, two brain regions which are indispensable in motor function. These neurones contain dopamine (DA), and it is the resultant decrease of DA due to neural death which leads to the onset of disease². Establishing a cause for PD is yet to be done, thus the main focus of clinicians treating patients with PD is symptomatic drug therapy. Most treatments revolve around the neurobiology of DA, with levodopa (L-DOPA) being the most common. L-DOPA is a precursor for intracellular synthesis of DA, by the enzyme dopa-decarboxylase. Because this enzyme only exists in dopaminergic neurones, as the progressive nature of the disease persists there will ultimately be no site of action remaining for L-DOPA. This has serious implications in the use of this drug for treating patients with PD. The fluctuations which occur between the positive and negative effects of L-DOPA mark the beginning of the end for the usefulness of this drug. This results in a process clinically referred to as the 'wearing-off' period, and after this period choice of therapy is very limited indeed³. Thus it is obvious why there is pertinent need for new treatments with higher efficacy and much more prolonged effect. Recently a newly discovered drug termed 'Movin' caused a stir in the research community, due to its positive effects against parkinsonian symptoms, when tested in an animal model of the disease⁸. This was the MPTP-treated primate model, which is known to be the most accurate reproduction of the human disease in animals. This model involves immunoreactive degeneration of neurones relevant to PD in the brain and has contributed significantly to developments in the fight against PD⁴. The data shows that a modest dose of the drug (when compared to current drugs) is of use in reducing PD related symptoms such as akinesia and rigidity, though the mechanisms involved in doing so remain to be elucidated. Therefore I wish in this proposal to study the effects of Movin as a potential treatment for PD and determine a putative understanding of its mechanism for action. I will achieve this by using rodent models of the disease (presented below); which like the MPTP-primate model, have proven to be of great value, and were amongst the first animal models to accurately recreate parkinsonian symptoms.

Preliminary Results:

THE LOSS OF MOVEMENT =
A LOSS OF TIME ?

Experiment 1:

The reserpine rodent model of Parkinson's disease is a well established test for the effect of drugs against PD. Reserpine binds to vesicular monoamine transporter 2 (VMAT-2) and prevents storage of DA in vesicles, this causes DA to build up in the cytosol of the neurone. Independent of exocytosis DA is released into the synaptic cleft and causes a brief augmentation of dopaminergic function, after which the depleted neurones no longer partake in DA transmission. The effects of reserpine closely mimic the decline in motility associated with PD. Addition of L-DOPA reverses the effects of reserpine as is shown in the following experiment:

The activity of mice running on a rotating treadmill was recorded after administration of the aforementioned drugs. Mice were tested against a negative control mouse which did not receive any drug. The activity of each mouse was determined by the number of rotations resulted from its walking or running in the treadmill. We quantified these rotations by use of magnets which passed each other upon every full rotation, and total number of rotations was saved by a computer linked to the apparatus. The drug dependent models we used in this study are listed below:

Malady, Malaise, Maladaptation

Alberto Vallejo



23

24

25

26

27

31

32

33

34

35

39

40

41

42

43

47

48

49

50

51

55

56

57

58

59


Nov


36	37	38	39	40	41
42	43	44	45	46	47
48	49	50	51	52	53
54	55	56	57	58	59
60	61	62	63	64	65
66	67	68	69	70	71
72	73	74	75	76	77

M. B.


8/5
NAB


64	65	66	67	
71	72	73	74	75
79	80	81	82	83
87	88	89	90	91
95	96	97	98	99





© J. L. N. 20





Abbas Zahedi es un artista cuya práctica interdisciplinaria combina la filosofía, lo poético y dinámicas sociales contemporáneas con el sonido, la escultura y otros medios performativos. Prestando especial atención a cómo se entrelazan las historias personales y colectivas, Zahedi establece conexiones siempre que es posible con quienes están alrededor, en la proximidad o involucrados en las situaciones particulares en las que su trabajo se centra.

Alberto Vallejo es un artista y comisario que reside en Madrid, donde desde 2017 co-comisaría el espacio de arte independiente Yaby.

jufjuf.org